The multiple sclerosis study published in the journal The Lancet found that alemtuzumab significantly reduced the number of attacks or relapses by people with MS.
This result was seen both in patients who had not previously received any treatment and those who have continued to show disease activity while taking an existing treatment for MS.
In one trial with patients who had recently relapsed, new episodes were reduced by 49% more than that achieved by the current standard treatment.
Over a two-year period, 65% of patients on alemtuzumab compared with 47% of patients on interferon did not relapse.
More top news
Police carried out a "proactive" operation after receiving reports that other concerts by the band had seen lots of mobile phone thefts.
The child died on her injuries and another 14-year-old girl was injured after the buggy they were travelling in was involved in a car crash.
Cloud thickening from the west throughout the day. Rain in northwest later.